These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 19043778)

  • 41. ADC histograms predict response to anti-angiogenic therapy in patients with recurrent high-grade glioma.
    Nowosielski M; Recheis W; Goebel G; Güler O; Tinkhauser G; Kostron H; Schocke M; Gotwald T; Stockhammer G; Hutterer M
    Neuroradiology; 2011 Apr; 53(4):291-302. PubMed ID: 21125399
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Phase 1 dose-escalation study of the antiplacental growth factor monoclonal antibody RO5323441 combined with bevacizumab in patients with recurrent glioblastoma.
    Lassen U; Chinot OL; McBain C; Mau-Sørensen M; Larsen VA; Barrie M; Roth P; Krieter O; Wang K; Habben K; Tessier J; Lahr A; Weller M
    Neuro Oncol; 2015 Jul; 17(7):1007-15. PubMed ID: 25665807
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Bevacizumab at recurrence in high-grade glioma.
    Salmaggi A; Gaviani P; Botturi A; Lamperti E; Simonetti G; Ferrari D; Silvani A
    Neurol Sci; 2011 Nov; 32 Suppl 2():S251-3. PubMed ID: 21987287
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Antiangiogenic therapy with bevacizumab in recurrent malignant gliomas: analysis of the response and core pathway aberrations.
    Zhang W; Qiu XG; Chen BS; Li SW; Cui Y; Ren H; Jiang T
    Chin Med J (Engl); 2009 Jun; 122(11):1250-4. PubMed ID: 19567132
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A phase II trial of single-agent bevacizumab in patients with recurrent anaplastic glioma.
    Kreisl TN; Zhang W; Odia Y; Shih JH; Butman JA; Hammoud D; Iwamoto FM; Sul J; Fine HA
    Neuro Oncol; 2011 Oct; 13(10):1143-50. PubMed ID: 21865400
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Outcomes of salvage fractionated re-irradiation combined with bevacizumab for recurrent high-grade gliomas that progressed after bevacizumab treatment*.
    Yonezawa H; Ohno M; Igaki H; Miyakita Y; Takahashi M; Tamura Y; Shima S; Matsushita Y; Ichimura K; Narita Y
    Jpn J Clin Oncol; 2021 Jul; 51(7):1028-1035. PubMed ID: 33959771
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Procarbazine, lomustine and vincristine for recurrent high-grade glioma.
    Parasramka S; Talari G; Rosenfeld M; Guo J; Villano JL
    Cochrane Database Syst Rev; 2017 Jul; 7(7):CD011773. PubMed ID: 28744879
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Early response evaluation for recurrent high grade gliomas treated with bevacizumab: a volumetric analysis using diffusion-weighted imaging.
    Hwang EJ; Cha Y; Lee AL; Yun TJ; Kim TM; Park CK; Kim JH; Sohn CH; Park SH; Kim IH; Heo DS; Lee SH; Choi SH
    J Neurooncol; 2013 May; 112(3):427-35. PubMed ID: 23417358
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Single-agent bevacizumab is an effective treatment in recurrent glioblastoma.
    Hacibekiroglu I; Kodaz H; Erdogan B; Turkmen E; Ozcelik M; Esenkaya A; Saygi HM; Uzunoglu S; Cicin I
    Med Oncol; 2015 Feb; 32(2):460. PubMed ID: 25572814
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Rebound tumour progression after the cessation of bevacizumab therapy in patients with recurrent high-grade glioma.
    Zuniga RM; Torcuator R; Jain R; Anderson J; Doyle T; Schultz L; Mikkelsen T
    J Neurooncol; 2010 Sep; 99(2):237-42. PubMed ID: 20151176
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Phase I trial of irinotecan plus temozolomide in adults with recurrent malignant glioma.
    Reardon DA; Quinn JA; Rich JN; Desjardins A; Vredenburgh J; Gururangan S; Sathornsumetee S; Badruddoja M; McLendon R; Provenzale J; Herndon JE; Dowell JM; Burkart JL; Newton HB; Friedman AH; Friedman HS
    Cancer; 2005 Oct; 104(7):1478-86. PubMed ID: 16088964
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Discriminant analysis of ¹⁸F-fluorothymidine kinetic parameters to predict survival in patients with recurrent high-grade glioma.
    Wardak M; Schiepers C; Dahlbom M; Cloughesy T; Chen W; Satyamurthy N; Czernin J; Phelps ME; Huang SC
    Clin Cancer Res; 2011 Oct; 17(20):6553-62. PubMed ID: 21868765
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival.
    Narayana A; Kelly P; Golfinos J; Parker E; Johnson G; Knopp E; Zagzag D; Fischer I; Raza S; Medabalmi P; Eagan P; Gruber ML
    J Neurosurg; 2009 Jan; 110(1):173-80. PubMed ID: 18834263
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Multimodality management of recurrent adult malignant gliomas: results of a phase II multiagent chemotherapy study and analysis of cytoreductive surgery.
    Rostomily RC; Spence AM; Duong D; McCormick K; Bland M; Berger MS
    Neurosurgery; 1994 Sep; 35(3):378-88; discussion 388. PubMed ID: 7800129
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Response and progression in recurrent malignant glioma.
    Hess KR; Wong ET; Jaeckle KA; Kyritsis AP; Levin VA; Prados MD; Yung WK
    Neuro Oncol; 1999 Oct; 1(4):282-8. PubMed ID: 11550320
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Irradiation and bevacizumab in high-grade glioma retreatment settings.
    Niyazi M; Ganswindt U; Schwarz SB; Kreth FW; Tonn JC; Geisler J; la Fougère C; Ertl L; Linn J; Siefert A; Belka C
    Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):67-76. PubMed ID: 21030162
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Bevacizumab and dose-intense temozolomide in recurrent high-grade glioma.
    Verhoeff JJC; Lavini C; van Linde ME; Stalpers LJA; Majoie CBLM; Reijneveld JC; van Furth WR; Richel DJ
    Ann Oncol; 2010 Aug; 21(8):1723-1727. PubMed ID: 20064829
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Carmustine (BCNU) plus Teniposide (VM26) in recurrent malignant glioma.
    Mack F; Schäfer N; Kebir S; Stuplich M; Schaub C; Niessen M; Scheffler B; Herrlinger U; Glas M
    Oncology; 2014; 86(5-6):369-72. PubMed ID: 24942787
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Retrospective analysis of 24 recurrent glioblastoma after chemoradiation and treated with nitrosoureas or irinotecan and bevacizumab].
    Vauleon E; Mesbah H; Gedouin D; Lecouillard I; Louvel G; Hamlat A; Riffaud L; Carsin B; Quillien V; Audrain O; Lesimple T
    Bull Cancer; 2012 Feb; 99(2):121-6. PubMed ID: 22257744
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A prospective phase II single-institution trial of sunitinib for recurrent malignant glioma.
    Pan E; Yu D; Yue B; Potthast L; Chowdhary S; Smith P; Chamberlain M
    J Neurooncol; 2012 Oct; 110(1):111-8. PubMed ID: 22832897
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.